STOCK TITAN

Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cytek Biosciences, Inc. granted Chief Legal Officer and Secretary Ilan Feuchtwang new equity awards. The awards consist of 241,416 Restricted Stock Units, each representing one share of common stock, and an option for 127,118 shares of common stock at an exercise price of $4.66 per share, expiring on August 9, 2036. The RSUs and options vest over four years under specified installment schedules, in each case subject to the executive’s Continuous Service under the company’s 2021 Equity Incentive Plan.

Positive

  • None.

Negative

  • None.
Insider Feuchtwang Ilan
Role Chief Legal Officer, Secretary
Type Security Shares Price Value
Grant/Award Restricted Stock Units F1, F2 241,416 $0.00 $0.00
Grant/Award Employee Stock Option (right to buy) F3 127,118 $0.00 $0.00
Holdings After Transaction: Restricted Stock Units — 241,416 shares (Direct); Employee Stock Option (right to buy) — 127,118 shares (Direct)
Footnotes (3)
  1. F1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
  2. F2. The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))).
  3. F3. The shares subject to the option shall vest over 4 years with 25% vesting on August 10, 2027 and 1/48 of the shares vesting each month thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the 2021 Plan)).
RSUs granted 241,416 units Restricted Stock Units representing common stock granted to Ilan Feuchtwang on August 10, 2026
Options granted 127,118 shares Employee stock option for common stock granted on August 10, 2026
Option exercise price $4.66 per share Exercise price for 127,118-share employee stock option expiring August 9, 2036
Option expiration date August 9, 2036 Expiration of employee stock option for 127,118 shares of common stock
RSUs following transaction 241,416 units Total RSUs held directly after the grant transaction
Options following transaction 127,118 shares Total option shares held directly after the grant transaction
Initial RSU vest date August 18, 2027 12/48 of the RSUs vest on this date, subject to Continuous Service
Initial option vest date August 10, 2027 25% of the option shares vest on this date, with monthly vesting thereafter
Restricted Stock Units financial
"Each restricted stock unit (the "RSU") represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Option financial
"The shares subject to the option shall vest over 4 years"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Continuous Service financial
"subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021"
2021 Equity Incentive Plan financial
"as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan")"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Cytek Biosciences (CTKB) grant to Ilan Feuchtwang?

Cytek Biosciences granted Ilan Feuchtwang 241,416 RSUs and an employee stock option for 127,118 shares of common stock at an exercise price of $4.66 per share, both vesting over four years.

How many Cytek Biosciences (CTKB) RSUs were awarded and how do they vest?

Ilan Feuchtwang received 241,416 RSUs, each for one share of common stock. They vest over four years in multiple scheduled tranches beginning on August 18, 2027, subject to his Continuous Service under the 2021 Equity Incentive Plan.

What are the key terms of the Cytek Biosciences (CTKB) stock option grant?

The employee stock option covers 127,118 shares of common stock at an exercise price of $4.66 per share. It vests over four years, starting with 25% on August 10, 2027, and expires on August 9, 2036.

When do Ilan Feuchtwang’s Cytek Biosciences (CTKB) RSUs begin vesting?

The RSUs begin vesting on August 18, 2027, when 12/48 of the 241,416 RSUs vest. Additional installments vest on specified dates in November, March, May, and August each year, subject to Continuous Service.

What does Continuous Service mean for Cytek Biosciences (CTKB) equity vesting?

Both the 241,416 RSUs and the option for 127,118 shares vest only while Ilan Feuchtwang maintains Continuous Service, as defined in Cytek’s 2021 Equity Incentive Plan, meaning ongoing qualifying service with the company.

How many Cytek Biosciences (CTKB) shares does Ilan Feuchtwang hold from these new awards?

After these grants, Ilan Feuchtwang holds 241,416 RSUs and an option covering 127,118 shares of common stock from the reported awards, all subject to the disclosed vesting schedules and conditions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feuchtwang Ilan

(Last)(First)(Middle)
C/O CYTEK BIOSCIENCES, INC.
47215 LAKEVIEW BOULEVARD

(Street)
FREMONT CALIFORNIA 94538

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer, Secretary
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)08/10/2026A241,416 (2) (2)Common Stock241,416$0241,416D
Employee Stock Option (right to buy)$4.6608/10/2026A127,118 (3)08/09/2036Common Stock127,118$0127,118D
Explanation of Responses:
1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))).
3. The shares subject to the option shall vest over 4 years with 25% vesting on August 10, 2027 and 1/48 of the shares vesting each month thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the 2021 Plan)).
/s/ Wenbin Jiang, Attorney-in-Fact08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)